Microvascular rarefaction in vascular cognitive impairment and heart failure: CRUCIA

European Commission0 个研究点目标入组 395 人开始时间: 2020年2月12日最近更新: 2024年5月27日

试验速览

2023 Protocol article in https://doi.org/10.1159/000529067 (added 03/05/2023)

•The MAASTRICHT cohort
•1. Cognitive complaints
•2. Signs of cerebral small vessel disease on brain MRI defined as at least Fazekas grade > 1
•3. < 26 on the Montreal Cognitive Assessment
•4. Aged 60 to 80 years
•The PAMPLONA-HFpEF cohort
•1. Clinical symptoms of HFpEF of hypertensive or valvular origin (classified according to the current guidelines of the European Society of Cardiology, or ESC)
•2. Structural and/or functional alterations such as left ventricular hypertrophy, left atrial dilation, and diastolic dysfunction but clinical symptoms not yet developed
•3. Aged 45-85 years
•The RELIEF-AS II cohort
•1. Severe aortic stenosis
•2. Suitable for aortic valve replacement surgery
•3. 50 to 85 years
•The UCL BIRTH cohort
•1. Aged 60-80 years

•1. Pregnancy and/or lactation
•2. eGFR <30ml/min
•3. Magnetic resonance incompatible devices
•4. Inability to complete the study
•The MAASTRICHT cohort
•1. Non-vascular cause for the cognitive deficit. Clinical evidence of neurodegenerative disease(s) such as Alzheimer’s Disease, frontotemporal dementia, Lewy Body disease, or hypokinetic rigid syndrome
•2. Lack of independence in daily living and/or a clinical dementia rating =1.0
•3. Lack of capacity to consent to participate
•The PAMPLONA-HFpEF cohort
•1. Severe bone or metabolic disease
•2. Active neoplasia
•3. Flow-limiting coronary artery disease >50% stenosis or prior myocardial infarction
•4. LVEF <50%.
•The RELIEF-AS II cohort
•1. Flow-limiting coronary artery disease >50% stenosis

发起方